COL19A1 and amyotrophic lateral sclerosis: Interestingly, ALS patients that showed COL19A1 levels below average from symptom onset (0.819) also showed a longer life expectancy and a light and progressive change in the ALSFRS-r scores at sampling in the follow-up period along disease progression than patients that showed COL19A1 levels above average (Fig. 4B).